Navigation Links
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients With Sickle Cell Disease Using Altemia Capsules
Date:7/26/2017

RIVIERA BEACH, Fla., July 26, 2017 /PRNewswire/ -- Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the completion of enrollment of our clinical trial evaluating AltemiaTM, an oral therapy for pediatric patients with Sickle Cell Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, multi-center study to evaluate the efficacy and safety of AltemiaTM in pediatric patients aged 5-17 years old. This trial is conducted under US IND 125274.

"The completion of enrollment in this study represents an important milestone for SPCI and our lead program for SCA and SCD," said Dr. Fred Sancilio, President and Chief Executive Officer of SPCI. "We are very encouraged by the high retention rate and adherence to treatment seen thus far in the study.  This study will further our understanding of the impact of AltemiaTM on Sickle Cell Disease."

Adrian L. Rabinowicz, M.D, SPCI's Chief Medical Officer, stated, "The faster than expected enrollment in this study highlights the intense interest and enthusiasm of the investigators, their staffs, as well as the patients and their families in achieving this important step for our development program. We look forward to reporting top-line results from the study early Q4 this year."

For more information about the SCOT Trial, please visit https://clinicaltrials.gov/ct2/show/NCT02973360.

For more information about AltemiaTM, please visit Altemia4sicklecell.com.

About Sickle Cell Disease

Sickle Cell Disease (SCD) and Sickle Cell Anemia (SCA) are a group of genetic disorders that result in dysfunctional hemoglobin and a depletion of certain fatty acids in the membrane of red and white blood cells. These abnormalities increase the red and white blood cells tendency to adhere to each other, which results in episodic occlusions of blood vessels, reperfusion damage, and excruciating pain. Ultimately, many children develop end organ damage and strokes. There are approximately 100,000 cases of SCD in the United States and millions outside of the United States.  Treatment options are limited.

About Sancilio Pharmaceuticals Company, Inc.

Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies® (ALT®) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT® platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT® platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT® platform, we make use of, and license rights to, our proprietary ALT® platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services. More information is available at Sancilio.com.

Contacts
Sancilio Pharmaceuticals Company, Inc.
Marc Wolff, 561-847-2302
Executive Vice President & Chief Financial Officer

Related Links

Sancilio Pharmaceuticals

View original content with multimedia:http://www.prnewswire.com/news-releases/sancilio-pharmaceuticals-company-inc-announces-completion-of-enrollment-in-the-scot-trial-in-pediatric-patients-with-sickle-cell-disease-using-altemia-capsules-300494609.html


'/>"/>
SOURCE Sancilio Pharmaceuticals Company, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. Access Pharmaceuticals Reports First Quarter Results
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
7. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
10. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
Breaking Medicine News(10 mins):